Zymeworks Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ZYME Nasdaq 8731 https://www.zymeworks.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zymeworks Inc

Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting - Mar 14th, 2023 8:30 pm
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results - Mar 7th, 2023 9:05 pm
Zymeworks Announces Participation in Upcoming Investor Conferences - Feb 28th, 2023 1:30 pm
Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call - Feb 21st, 2023 1:30 pm
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma - Jan 19th, 2023 12:45 pm
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 - Jan 4th, 2023 9:15 pm
Zymeworks Announces Participation in Upcoming Investor Conference - Dec 21st, 2022 12:30 pm
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab - Dec 21st, 2022 12:30 pm
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab - Dec 19th, 2022 12:00 pm
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium - Dec 14th, 2022 9:15 pm
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS - Dec 9th, 2022 1:00 pm
Zymeworks to Transfer Stock Listing to Nasdaq - Dec 5th, 2022 1:30 pm
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals - Nov 29th, 2022 1:30 pm
Why Zymeworks Inc. (ZYME) Might be Well Poised for a Surge - Nov 24th, 2022 5:20 pm
Wall Street Analysts Believe Zymeworks Inc. (ZYME) Could Rally 59%: Here's is How to Trade - Nov 22nd, 2022 2:55 pm
Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option - Nov 21st, 2022 5:22 pm
Zymeworks Inc. (ZYME) Just Flashed Golden Cross Signal: Do You Buy? - Nov 21st, 2022 2:55 pm
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS) - Nov 21st, 2022 2:00 pm
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates - Nov 8th, 2022 10:45 pm
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results - Nov 8th, 2022 9:22 pm